^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Shan Ke Yu (socazolimab)

    i
    Other names: STI-A1014, ZKAB 001, ZKAB001, STI A1014, STIA1014
    Company:
    Lee's Pharm, Sorrento
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    4ms
    A clinical study to evaluate the efficacy and safety of socazolimab combined with bevacizumab and lenvatinib in the conversion therapy of advanced liver cancer (ChiCTR2500106449)
    P=N/A, N=30, Recruiting, Hubei Cancer Hospital; Hubei Cancer Hospital
    New trial
    |
    Avastin (bevacizumab) • Lenvima (lenvatinib) • Shan Ke Yu (socazolimab)
    7ms
    Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=440, Recruiting, Lee's Pharmaceutical Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Shan Ke Yu (socazolimab)
    8ms
    Promising outcomes of the PD-L1 inhibitor Socazolimab in recurrent and metastatic cervical cancer: a case report. (PubMed, Front Oncol)
    In this report, the safety profile of Socazolimab was favorable, with no severe or uncontrollable adverse events. This case provides compelling evidence of the antitumor activity and manageable toxicity of Socazolimab in metastatic cervical cancer patients, offering valuable insights for further research and clinical application of the drug.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Shan Ke Yu (socazolimab)
    1year
    Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. (PubMed, Oncologist)
    Socazolimab combined with nab-paclitaxel has shown good safety and promising antitumor activity as first-line therapy in patients with advanced urothelial carcinoma.
    P1 data • Journal • Combination therapy • Metastases
    |
    PD-1 (Programmed cell death 1)
    |
    albumin-bound paclitaxel • Shan Ke Yu (socazolimab)
    over1year
    Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, Lee's Pharmaceutical Limited
    New P3 trial • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Shan Ke Yu (socazolimab)
    almost2years
    A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC (clinicaltrials.gov)
    P3, N=498, Completed, Lee's Pharmaceutical Limited | Recruiting --> Completed
    Trial completion
    |
    PD-L1 expression
    |
    carboplatin • etoposide IV • Shan Ke Yu (socazolimab)
    almost3years
    First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001. (PubMed, Clin Cancer Res)
    Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized osteosarcoma patients.
    P1/2 data • Journal
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Shan Ke Yu (socazolimab)
    over4years
    A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P1, N=101, Recruiting, Lee's Pharmaceutical Limited | N=15 --> 101
    Clinical • Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Shan Ke Yu (socazolimab)